Compugen Ltd. (NASDAQ:CGEN) Holdings Raised by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. grew its position in Compugen Ltd. (NASDAQ:CGEN) by 75.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,350 shares of the biotechnology company’s stock after acquiring an additional 8,350 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Compugen were worth $35,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the company. Joel Isaacson & Co. LLC increased its holdings in shares of Compugen by 136.4% in the 3rd quarter. Joel Isaacson & Co. LLC now owns 52,000 shares of the biotechnology company’s stock valued at $94,000 after acquiring an additional 30,000 shares during the last quarter. Squarepoint Ops LLC increased its holdings in shares of Compugen by 23.4% in the 2nd quarter. Squarepoint Ops LLC now owns 85,693 shares of the biotechnology company’s stock valued at $144,000 after acquiring an additional 16,253 shares during the last quarter. Rothschild Investment LLC bought a new stake in shares of Compugen in the 2nd quarter valued at approximately $380,000. ARK Investment Management LLC increased its holdings in shares of Compugen by 4.7% in the 2nd quarter. ARK Investment Management LLC now owns 1,088,271 shares of the biotechnology company’s stock valued at $1,850,000 after acquiring an additional 48,979 shares during the last quarter. Finally, Secure Asset Management LLC acquired a new position in Compugen during the 2nd quarter valued at approximately $69,000. 12.22% of the stock is currently owned by institutional investors.

Compugen Price Performance

NASDAQ:CGEN opened at $1.41 on Friday. Compugen Ltd. has a 12-month low of $0.62 and a 12-month high of $3.03. The firm has a market capitalization of $125.82 million, a P/E ratio of 70.50 and a beta of 2.64. The business has a 50 day simple moving average of $1.70 and a 200 day simple moving average of $1.85.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.20). Compugen had a return on equity of 2.62% and a net margin of 2.67%. The business had revenue of $17.13 million for the quarter, compared to analyst estimates of $17.67 million. During the same quarter last year, the firm posted ($0.11) EPS. Research analysts anticipate that Compugen Ltd. will post 0.11 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, StockNews.com upgraded Compugen from a “hold” rating to a “buy” rating in a research report on Thursday, August 15th.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.